Healthcare Services company Metropolis Healthcare announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Metropolis records revenue of Rs 345 crore in Q4FY25. B2C revenues saw a robust 14% YoY growth in Q4FY25. B2B revenue grew 10% YoY in Q4FY25 Adjusted EBITDA: Rs 84 crore in Q4FY25 vs. Rs 80 crore in Q4FY24 — up 5% Profit After Tax (PAT): Rs 29 crore in Q4FY25 vs. Rs 36 crore in Q4FY24 — down 19% FY25 Financial Highlights: Metropolis records revenue of Rs 1,331 crore in FY25 Patient volume grew by 6% YoY and Test Volume grew by 7%, in FY25 B2C revenues saw a robust 17% YoY growth in FY25 B2B revenue grew 12% YoY in FY25 Adjusted EBITDA: Rs 325 crore in FY25 vs. Rs 285 crore in FY24 — up 14% Profit After Tax (PAT): Rs 146 crore in FY25 vs. Rs 128 crore in FY24 — up 14% Expanded to 750+ towns in FY25 with addition of 29 new labs and 400 centres in FY25, enhancing last-mile access. Ameera Shah, Executive Chairperson & Whole-time Director, Metropolis Healthcare said, “Over the past four years, Metropolis has built a resilient, future-ready organization through strategic investments in laboratories, network expansion, brand, technology, and talent. Despite a challenging environment, we have strengthened our scientific leadership, enhanced customer engagement, and driving operational excellence. We are confident that our recent acquisitions — Core Diagnostics, Scientific Pathology, and Dr. Ahuja’s Pathology & Imaging Centre — will generate strong returns and fuel the next phase of growth. These acquisitions reinforce our leadership in specialty testing, expand our B2C footprint, and strengthen our regional presence in North India. With a robust foundation, a differentiated portfolio in high-growth segments, and a deeper penetration across key regions, Metropolis is well positioned to capitalize on emerging opportunities and drive long-term stakeholder value." Surendran Chemmenkotil, Chief Executive Officer, Metropolis Healthcare said, “FY25 has been a pivotal year in our journey toward becoming a more consumer-centric and digitally enabled diagnostics brand. Our growth was fuelled by rising demand for preventive and specialized testing, enabled by focused execution, stronger clinician engagement, and meaningful innovation. We introduced industry-first cancer screening panels and tools, along with AI-powered diagnostics to enhance accuracy and enable early detection. Our proprietary engine, MetAdvisor, uses historical data to deliver personalized, science-led test recommendations—boosting TruHealth performance. As we look ahead, our focus is on strengthening our presence in key cities, expanding digital access, and advancing evidence-based preventive care. With science at the heart of our efforts, we aim to make quality diagnostics more accessible, reliable, and impactful for the communities we serve.” Result PDF
Conference Call with Metropolis Healthcare Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.